{"news_desk": "Business", "print_page": "4", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Eli Lilly says it is stopping development of drug for cardiovascular disease because drug is not likely to be determined effective in preventing heart attacks and strokes.", "type_of_material": "News", "word_count": "722", "lead_paragraph": "The drug was expected to be a blockbuster, but its maker said it was not likely to be found effective in preventing heart attacks and strokes.", "pub_date": "2015-10-13T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Eli Lilly Abandons Heart Disease Drug in Final Stage of Trials", "print_headline": "Lilly Drops Heart Drug in Last Stage of Its Trials"}, "snippet": "The drug was expected to be a blockbuster, but its maker said it was not likely to be found effective in preventing heart attacks and strokes.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/10/13/business/eli-lilly-abandons-heart-disease-drug-in-final-stages-of-trials.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Eli Lilly and Company", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Heart", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Clinical Trials", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Cholesterol", "name": "subject"}], "blog": [], "_id": "561bb5df38f0d839bd911198", "source": "The New York Times"}